Investor Presentation

49 Investor presentation First six months of 2022 Novo Nordisk global insulin market leadership at 47.1% and the global insulin volume market grew by 1.1% North America Operations Market growth: -1.3% MS: 38.4% MS gain/loss': -0.8%-p Sales growth: -18% USA Market growth: -1.3% MS: 37.9% MS gain/loss1: -1.1%-p Sales growth: -19% EMEA Global Market growth: 1.1% MS 47.1% MS gain/loss1: -0.1%-p Sales growth: -8%: Novo NordiskⓇ International Operations Market growth: 2.0% MS: 50.3% MS gain/loss1: 0.1%-p Sales growth: -5% Market growth: -1.9% MS: 57.1% MS gain/loss1: -0.2%-p Sales growth: 1% Region China Market growth: 5.2% MS: 50.5% MS gain/loss1: -0.2%-p Sales growth: -17% Market growth: 2.4% MS: 47.8% ROW MS gain/loss1: 0.4%-p Sales growth: 1% Source: IQVIA MAT, May 2022 volume figures Note: Sales growth for first six months of 2022 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with May 2021 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; RoW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong

View entire presentation